Advertisement

Which Is the Ideal Drug for Chronic Prophylaxis of Atrial Fibrillation?

  • G. Boriani
  • M. Biffi
  • I. Diemberger
  • C. Martignani
  • C. Camanini
  • C. Valzania
  • G. Domenichini
  • I. Corazza
  • A. Branzi
Conference paper

Abstract

A series of antiarrhythmic agents have been demonstrated to be highly effective in terminating recent-onset atrial fibrillation, class IC agents being the most effective [1, 2]. In contrast with the high efficacy shown in treating recent-onset atrial fibrillation, results obtained in preventing recurrences of atrial fibrillation are scanty [3–6]. Table 1 summarizes reported data from the literature. As shown, the percentage of patients who maintain sinus rhythm without arrhythmia recurrence under placebo treatment is around 30% after 3–6 months and around 20%–25% after 12 months. Antiarrhythmic agents may increase the percentage of patients who maintain sinus rhythm, but the overall efficacy is limited and, except for amiodarone, no more than 50% of the treated patients are free from arrhythmia recurrences after 6–12 months. For amiodarone, efficacy rates of 75%–78.5% at 6 months and of 50%–73% at 12 months have been reported.

Keywords

Atrial Fibrillation Sinus Rhythm Atrial Flutter Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boriani G, Biffi M, Capucci A et al (1997) Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 126:621–625PubMedGoogle Scholar
  2. 2.
    Boriani G, Biffi M, Capucci A et al (1998) Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol 21:2470–2474PubMedCrossRefGoogle Scholar
  3. 3.
    Boriani G, Biffi M, Branzi A et al (1998) Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response. Arch Gerontol Geriatr 27:127–139PubMedCrossRefGoogle Scholar
  4. 4.
    Jung F, DiMarco JP (1998) Treatment strategies for atrial fibrillation. Am J Med 104:272–286PubMedCrossRefGoogle Scholar
  5. 5.
    Van Gelder IC, Crijns HJ (1998) Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. Pacing Clin Electrophysiol 20:2675–2683CrossRefGoogle Scholar
  6. 6.
    Allessie MA (1998) Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 9:1378–1393PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson JL, Gilbert EM, Alpert BL et al (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80:1557–1570PubMedCrossRefGoogle Scholar
  8. 8.
    Pietersen AH, Hellemann H (1991) Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 67:713–717PubMedCrossRefGoogle Scholar
  9. 9.
    Naccarelli G, Dorian P, Hohnloser SH et al (1996) Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 77:53A–59APubMedCrossRefGoogle Scholar
  10. 10.
    van Wijk LM, den Heijer P, Crijns HJ et al (1989) Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 13:32–36PubMedCrossRefGoogle Scholar
  11. 11.
    Van Gelder IC, Crijns HJ, Van Gilst WH et al (1989) Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 64:1317–1321PubMedCrossRefGoogle Scholar
  12. 12.
    Vorperian VR, Havighurst TC, Miller S et al (1997) Adverse effects of low dose amio-darone: a meta-analysis. J Am Coll Cardiol 30:791–798PubMedCrossRefGoogle Scholar
  13. 13.
    Roy D, Talajic M, Dorian P et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342:913–920PubMedCrossRefGoogle Scholar
  14. 14.
    Chun SH, Sager PT, Stevenson WG et al (1995) Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 76:47–50PubMedCrossRefGoogle Scholar
  15. 15.
    Horowitz LN, Spielman SR, Greenspan AM et al (1985) Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 6:1402–1407PubMedCrossRefGoogle Scholar
  16. 16.
    Tuzcu EM, Gilbo J, Masterson M et al (1989) The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve Clin J Med 56:238–242PubMedGoogle Scholar
  17. 17.
    Vitolo E, Tronci M, Larovere M et al (1981) Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 36:431–434PubMedGoogle Scholar
  18. 18.
    Kerin NZ, Faitel K, Naini M (1996) The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med 156:49–53PubMedCrossRefGoogle Scholar
  19. 19.
    Opolski G, Stanislawska J, Gorecki A et al (1997) Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol 20:337–340PubMedCrossRefGoogle Scholar
  20. 20.
    Gosselink AT, Crijns HJ, Van Gelder IC et al (1992) Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267:3289–3293PubMedCrossRefGoogle Scholar
  21. 21.
    Gold RL, Haffajee CI, Charos G et al (1986) Amiodarone for refractory atrial fibrillation. Am J Cardiol 57:124–127PubMedCrossRefGoogle Scholar
  22. 22.
    Blevins RD, Kerin NZ, Benaderet D et al (1987) Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 147:1401–1404PubMedCrossRefGoogle Scholar
  23. 23.
    Brodsky MA, Allen BJ, Walker CJ 3rd et al (1987) Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 60:572–575PubMedCrossRefGoogle Scholar
  24. 24.
    Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102:2385–2390PubMedCrossRefGoogle Scholar
  25. 25.
    Greenbaum RA, Campbell TJ, Channer KS et al (1998) Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: the EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study. Circulation 98:1663–1Google Scholar
  26. 26.
    Falk RH (1998) Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 117:141–150Google Scholar
  27. 27.
    Waldo AL, Prystowsky EN (1998) Drug treatment of atrial fibrillation in the managed care era. Am J Cardiol 81:23C–29CPubMedCrossRefGoogle Scholar
  28. 28.
    Coplen SE, Antman EM, Berlin JA et al (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82:1106–1116PubMedCrossRefGoogle Scholar
  29. 29.
    Fuster V, Ryden LE, Asinger RW et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38:1231–1266PubMedCrossRefGoogle Scholar
  30. 30.
    Middlekauff HR, Wiener I, Saxon LA et al (1992) Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med 116:1017–1020PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • G. Boriani
    • 1
  • M. Biffi
    • 1
  • I. Diemberger
    • 1
  • C. Martignani
    • 1
  • C. Camanini
    • 1
  • C. Valzania
    • 1
  • G. Domenichini
    • 1
  • I. Corazza
    • 1
  • A. Branzi
    • 1
  1. 1.Institute of CardiologyUniversity of BolognaItaly

Personalised recommendations